Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia

American Journal of Health-System Pharmacy

Volumn 71, Issue 12, 2014, Pages 1001-1008

  Davis, Kyle A ^a   Miyares, Marta A ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; CARRIER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN;

CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LIVER FUNCTION TEST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; REVIEW; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DRUG INTERACTION; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; CARRIER PROTEINS; DRUG INTERACTIONS; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II;

EID: 84907224063     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130592     Document Type: Review

References (28)

1. Goldberg AC. Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors. J Clin Lipidol. 2013; 7(suppl 3):S16-20.
2. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm. 2013; 19:139-49.
3. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012; 223:262-8.
4. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol. 2013; 24:288-94.
5. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011; 5(suppl 3):S1-8.
6. Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta. 2000; 1486:72-83.
7. Joy TR, Hegele RA. Microsomal triglyceride transfer protein inhibition - friend or foe? Nat Clin Pract Cardiovasc Med. 2008; 5:506-8.
8. Lilly SM, Rader DJ. New targets and emerging therapies for reducing LDL cholesterol. Curr Opin Lipidol. 2007; 18:650-5.
9. Raval SK, Raval PS, Jain MR. Emerging therapies for dyslipidemia: known knowns and known unknowns of MTP inhibitors. Recent Pat Endocr Metab Immune Drug Discov. 2012; 6:24-9.
10. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013; 35:1082-98.
11. Food and Drug Administration. Briefing document: NDA 203858. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM323841.pdf (accessed 2013 Aug 25).
12. Center for Drug Evaluation and Research, Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s). Application number 203858 Orig1s000. www.accessdata.fda.gov/drugsatfda-docs/nda/2012/203858Orig1s000ClinpharmR.pdf (accessed 2013 Aug 25).
13. ClinicalTrials.gov. Study to determine the intra-subject variability of pharmacokinetics of lomitapide in healthy subjects (NCT01915771). http://clinicaltrials.gov/ct2/show/NCT01915771?term=lomitapide&rank=5 (accessed 2013 Aug 30).
14. ClinicalTrials.gov. Phase I study of the safety, tolerability, PK & PD of lomitapide in Japanese and Caucasian subjects with elevated LDL-C (NCT01760187). http://clinicaltrials.gov/ct2/show/NCT01760187?term=lomitapide&rank=2 (accessed 2013 Aug 30).
15. Juxtapid (lomitapide) package insert. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; 2012.
16. Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 356:148-56.
17. Wetterau JR, Lin MC, Jami l H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997; 1345:136-50.
18. Samaha FF, McKenney J, Bloedon LT et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008; 5:497-505.
19. Stern L, Iqbal N, Seshadri P et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004; 140:778-85.
20. Ikewaki K, Rader DJ, Zech LA, Brewer HB Jr. In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. J Lipid Res. 1994; 35:1809-19.
21. Ornish D, Scherwitz LW, Billings JH et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998; 280:2001-7. [Erratum, JAMA. 1999; 281:1380.]
22. Cuchel M, Meagher EA, du Toit Theron H et al., for the Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013; 381:40-6.
23. ClinicalTrials.gov. Evaluate safety and efficacy of AEGR-733 and atorvastatin vs atorvastatin monotherapy in hypercholesterolemia. http://clinicaltrials.gov/ct2/show/NCT00690443?term=lomitapide&rank=9 (accessed 2013 Aug 30).
24. ClinicalTrials.gov. Long term, follow-on study of lomitapide in patients with homozygous familial hypercholesterolemia. http://clinicaltrials.gov/ct2/show/NCT00943306?term=lomitapide&rank=1 (accessed 2013 Aug 30).
25. Tuteja S, Duffy D, Dunbar R et al. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy. 2013. Epub ahead of print. 2013 Oct 15.
26. Stein EA, Dufour R, Gagne C et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012; 126:2283-92.
27. McKenney JM, Koren MJ, Kereiakes DJ et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012; 59:2344-53.
28. Feuerstein A, for TheStreet, Inc. Aegerion CEO speaks on Juxtapid launch, orphan drug pricing and competition. www.thestreet.com/stor y/11826405/1/aegerion-ceo-speaks-on-juxtapid-launch-orphan-drug-pricing-and-competition.html (accessed 2013 Nov 6).